Physician profile

Arcot S Premkumar

Pulmonary Disease · Phoenix, AZ

NPI 1265496665

$13,743.53

in general payments reported to CMS, 2019-2025

41 companies · $133 in 2025

The $133 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,287.85
Education$215.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $1,766.33 2019-2025 Ofev, Jascayd
Astrazeneca Pharmaceuticals LP $1,716.94 2019-2024 Tezspire, Breztri, Fasenra
Glaxosmithkline, LLC. $1,436.06 2019-2024 Trelegy Ellipta, Nucala, Shingrix
Insmed, INC. $807.74 2019-2025 Arikayce
Philips North America LLC $803.80 2019-2025 Ambulatory Monitoring & Diagnostics Undivided, (7999) Src Undivided
Electromed, INC. $701.02 2019-2024 Smartvest
Genzyme Corporation $682.50 2019-2024
Regeneron Healthcare Solutions, INC. $669.97 2019-2024 Dupixent
Actelion Pharmaceuticals US, INC. $668.17 2019-2023 Opsumit, Uptravi
Genentech USA, INC. $650.72 2019-2023 Xolair
United Therapeutics Corporation $628.29 2019-2024 Tyvaso, Orenitram, Remodulin
Mylan Specialty L.P. $346.14 2019-2024 Yupelri
Takeda Pharmaceuticals U.S.A., INC. $319.36 2020-2024 Glassia
Amgen INC. $255.54 2021-2024 Tezspire
Sunovion Pharmaceuticals INC. $235.80 2019-2021
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Baxter Healthcare $231.10 2022-2025 Hillrom - Vest System Model 105 Home Care
Advanced Respiratory, INC $177.96 2019-2021
Grifols USA, LLC $160.90 2019-2022
Sandoz INC. $137.21 2019-2022
Allergan, INC. $107.13 2019-2020
Teva Pharmaceuticals USA, INC. $105.20 2021-2022
Intuitive Surgical, INC. $99.24 2022
Abbvie INC. $99.05 2022-2024
Novartis Pharmaceuticals Corporation $95.05 2019-2024
Janssen Pharmaceuticals, INC $93.62 2019-2020
Shire North American Group INC $86.09 2019
Sanofi-Aventis U.S. LLC $78.99 2023
Paratek Pharmaceuticals, INC. $73.27 2021-2022
Inogen, INC. $63.89 2023 Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator
Merck Sharp & Dohme LLC $61.03 2019-2022
Mallinckrodt Hospital Products INC. $59.01 2022
Bayer Healthcare Pharmaceuticals INC. $56.09 2019-2023
Jazz Pharmaceuticals INC. $55.79 2020-2021
Pulmonx Corporation $44.67 2019-2021
Vapotherm INC $36.56 2022
Gilead Sciences, INC. $32.11 2019
Inspire Medical Systems, INC. $26.23 2023 Inspire
Cvrx, INC. $22.57 2025 Barostim Neo System
Novo Nordisk INC $19.19 2025 Wegovy
Abbott Laboratories $17.37 2022
Circassia INC. $15.83 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Arcot S Premkumar

$13,743.53

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $133 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/103188/arcot-s-premkumar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.